Edgewise Therapeutics, Inc. (EWTX): Price and Financial Metrics
EWTX Price/Volume Stats
| Current price | $15.08 | 52-week high | $20.69 |
| Prev. close | $15.23 | 52-week low | $5.12 |
| Day low | $14.90 | Volume | 378,800 |
| Day high | $15.95 | Avg. volume | 932,471 |
| 50-day MA | $17.02 | Dividend yield | N/A |
| 200-day MA | $10.41 | Market Cap | 1.40B |
EWTX Stock Price Chart Interactive Chart >
Edgewise Therapeutics, Inc. (EWTX) Company Bio
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Latest EWTX News From Around the Web
Below are the latest news stories about EDGEWISE THERAPEUTICS INC that investors may wish to consider to help them evaluate EWTX as an investment opportunity.
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024BOULDER, Colo., December 19, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am PT (1:30 pm ET). |
Edgewise Therapeutics Launches First of Its Kind Educational Website Dedicated to the Becker Muscular Dystrophy CommunityBOULDER, Colo., December 18, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the launch of an educational website dedicated to the Becker muscular dystrophy (Becker) community: www.beckermusculardystrophy.com. This is the first website solely focused on providing Becker-specific resources to help individuals and caregivers better understand the disease, learn different approaches to care and stay up to date on advocacy partne |
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDABOULDER, Colo., November 30, 2023--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker) and Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne. EDG-5506 is an investigational orally administered small molecule designed to |
Speculator’s Watch List: 7 Stocks Ripe for a Short-Squeeze WindfallAlthough betting against the bears is risky, the rewards for targeting short-squeeze stocks can also be stratospheric. |
EWTX Price Returns
| 1-mo | -7.20% |
| 3-mo | -1.57% |
| 6-mo | 140.13% |
| 1-year | 109.44% |
| 3-year | -45.24% |
| 5-year | N/A |
| YTD | 37.84% |
| 2023 | 22.37% |
| 2022 | -41.49% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...